1. HBW Insight
  2. >>Beauty
  3. >>Policy & Regulation
  4. >>Regulation

2016 In Review: FDA Transparency, Claims Enforcement A One-Off?

 
• By Ryan Nelson

The Rose Sheet’s coverage of FDA’s warning letter crackdown and data sharing produced some of its most-read stories of 2016, based on online analytics. Legislative proposals and cosmetic safety issues in the US mainstream factored in the agency’s transparency work, a situation that may not repeat in the new year.

2016

FDA’s focus on anti-aging claims yielded an unprecedented number of warning letters to cosmetic manufacturers in 2016, a year in which the agency also provided an unusually high level of visibility into its cosmetics regulatory program and the safety data at its disposal.

Such trends likely do not reflect a shift in FDA policy as much as the unique combination of factors that distinguished 2016.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation